Anna Maria Villalobos, MD Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 2323 Memorial Ave, Suite 10, Lynchburg, VA 24501 Phone: 434-200-5200 Fax: 434-200-5213 |
Jesse Bennett Prillaman, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2323 Memorial Ave Ste 10, Lynchburg, VA 24501 Phone: 434-200-5200 |
David M Wodicka, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 2019 Tate Springs Rd, Lynchburg, VA 24501 Phone: 434-846-7374 Fax: 434-846-1910 |
Dr. Matthew Wayne Tatom, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2832 Candlers Mountain Rd, Lynchburg, VA 24502 Phone: 434-239-3949 Fax: 434-239-6982 |
News Archive
As the global market leader in human identification, Life Technologies Corporation announced today it signed a global exclusive agreement with LGC Forensics for the right to distribute ParaDNA, a portable rapid DNA system that determines the quality of human DNA faster and more economically than any existing method.
Minneapolis Star Tribune, on the Biotechnology Industry Organization's convention in Chicago: "The biotechnology industry, hurt by the recession, is looking for inspiration from Charles Darwin. Leading executives say unless biotech companies adapt to a less-robust economy and changing industry standards, they won't survive the downturn. Biotech start-ups, seen as the lifeblood of the industry, have been among the worst hit by a decline in venture capital investments."
Nigeria has been affected with an outbreak of the deadly Lassa fever since the start of this year. This disease typically has a high rate of fatality, no known cure and no vaccines have been developed against it yet. This is an unprecedented outbreak of this disease that is spreading faster than before. It is infecting more individuals than health workers can handle with their limited resources, say official sources.
Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that it has received notification from the US Food and Drug Administration (FDA) that the Agency is currently drafting a response to the Company relating to the Investigational New Drug (IND) Application it filed in November seeking clearance to initiate a Phase I/II multicenter study using embryonic stem cell derived retinal cells to treat patients with Stargardt's Macular Dystrophy (SMD).
› Verified 2 days ago